Cupping Therapy on Immune System in Post Covid -19

NCT05901337 | Completed

• 1 other identifier: No:P.T.REC/012/003554
• Study Type: interventional
• Target: 76
• Locations: 1 country
• Sites: 1

Brief Summary

Purpose of this study is to investigate

1. 1.The effect of Dry cupping therapy on T-Lymphocyte in post covid-19 patients.
2. 2.The effect of Dry cupping therapy on serum Cytokine in post covid-19 patients.
3. 3.The effect of Dry cupping therapy on Immunoglobulin IgA.
4. 4.The effect of Dry cupping therapy on Immunoglobulin IgM.
5. 5.The effect of Dry cupping therapy on Immunoglobulin IgG. seventy six patients of both genders with deficiency in T-Lymphocyte number,,higher level of serum cytokine and lower immunoglobulin IgA,IgM,IgG after two weeks of recovery from covid-19 . Age range from Twenty one to Sixty six years old .They participated in the study and recruited from surveillance unit of Shobra general hospital .These patients recruited by phone and have been offered to participate in the programme.The patients were divided equally into two groups (A and B). Assessment was done before and after treatment. T-Lymphocyte, serum cytokine and immunoglobulin IgA, IgM and IgG were analyzed by kenza 240 TX from fluorescence-labeled flow cytometry. Disposable cupping therapy instrument was used in treatment of group (A) in addition to traditional medical treatment in the form of vitamin C, D and anticoagulant drugs. Traditional medical treatment only was used in treatment of group (B).The obtained results of this study will determine the significant improvement of participated two groups.

Conditions

Covid-19 Patients

Outcome Measures

Primary Outcomes (3)

• T-lymphocyte

  1- Lymphocyte subset were analyzed from fluorescence-labeled flow cytometry on a DxFLEX flow cytometry by Kenza 240 Tx

  3months

• Serum Cytokine

  Cytokine detection Kenza reagents were provided from a 240 TX bio lap diagnostic apparatus by microsphere flow immunofluorescence

  3months

• ImmunoglobulinA,M,G

  Kenza 240 TX for detection of immunoglobulin

  3 months

Study Arms (2)

Cupping therapy with Convential medical treatment

ACTIVE COMPARATOR

Cupping therapy with Convential medical treatment

Combination Product: Cupping therapy with convential medical treatment; Drug: Convential medical treatment

Convential medical treatment

ACTIVE COMPARATOR

Convential medical treatment

Combination Product: Cupping therapy with convential medical treatment; Drug: Convential medical treatment

Interventions

Cupping therapy with convential medical treatment COMBINATION_PRODUCT

Device:Cupping therapy device Group A participants received Dry cupping therapy one session per week for 8 weeks with 6 days intervals between sessions and with cups applied to the skin for around 8 minutes. (In addition to convential medical treatment for 8 weeks in the form of : 1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger . 2. Vitamine C: The recommended dietary dose 200 mg/day vitamin c 3. Anticoagulation drugs ("blood thinners")Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours .

Convential medical treatment; Cupping therapy with Convential medical treatment

Convential medical treatment DRUG

Group B participants received convential medical treatment for 8 weeks in the form of : 1. Vitamin D: The recommended dietary dose of vitamin D is 600 IU each day for adults 70 and younger . 2. Vitamine C: The recommended dietary dose 200 mg/day vitamin C 3. Anticoagulation drugs ("blood thinners")Doctors usually prescribe low-molecular-weight heparin (enoxaparin) (30 mg), each given subcutaneously every 12 hours .

Convential medical treatment; Cupping therapy with Convential medical treatment

Eligibility Criteria

• Age: 21 Years - 66 Years
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• All patients with body mass index(BMI) 25.0-29.9 kg/m2 recruited two weeks post recovary from covid-19 and have lower T-lymphocyte and elevated cytokine All patients were clinically and medically stable.All patients recruited by phone and have been offered to participate in the programme.All patients will sign the informed consent before joining the study. Age range from 21 to 66 years .Subjects will be divided equally into two groups A,B. Assessment will be done before and after treatment.

You may not qualify if:

• Patients will be excluded if they have any of the following criteria:
• History of acute or chronic infections
• Hepatobiliary diseases
• Hematological diseases
• Urinary system diseases
• Nutrition and metabolism diseases
• Rheumatic diseases
• Endocrine diseases
• Circulatory system diseases
• Muscle trauma
• Hypertension Further, if they fulfilled any of the following testing criteria
• Hepatitis C virus antibodies
• Human immunodeficiency virus antibodies
• Creatinine above 120 μmol/L
• Creatine kinase above 500 U/L

Sponsors & Collaborators

• Cairo University: lead

Study Sites (1)

Faculty of physical therapy

Giza, Egypt

Location

MeSH Terms

Interventions

Cupping Therapy

Intervention Hierarchy (Ancestors)

Complementary Therapies; Therapeutics

Study Officials

• Marwa Mohamed, master

  Physiotherapist at Shoubra general hospital

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: RANDOMIZED
• Masking: SINGLE
• Who Masked: OUTCOMES ASSESSOR
• Masking Details: single
• Purpose: TREATMENT
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: PRINCIPAL INVESTIGATOR
• PI Title: Dr

Study Record Dates

• First Submitted: June 11, 2023
• First Posted: June 13, 2023
• Study Start: March 7, 2022
• Primary Completion: June 21, 2022
• Study Completion: June 1, 2023
• Last Updated: June 13, 2023

Record last verified: 2023-06

Data Sharing

• IPD Sharing: Will not share

Locations

EG (1)